Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Not yet recruiting 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Multiple Myeloma 47Leukemia, Myeloid, Acute 25Recurrence 21Lymphoma, Large B-Cell, Diffuse 13Sarcoma 9Lymphoma 6Neoplasms, Plasma Cell 5Neoplasm Metastasis 5Glioblastoma 5Endometrial Neoplasms 5Ovarian Neoplasms 4Neurofibrosarcoma 4Neoplasms 4Melanoma 4Lymphoma, T-Cell, Peripheral 4Lymphoma, Non-Hodgkin 4Colorectal Neoplasms 4Triple Negative Breast Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Myelodysplastic Syndromes 3Lymphoma, Extranodal NK-T-Cell 3Lymphoma, B-Cell 3Liposarcoma 3Glioma 3Carcinoma, Non-Small-Cell Lung 3Carcinoma 3Waldenstrom Macroglobulinemia 2Thymoma 2Sarcoma, Alveolar Soft Part 2Rhabdoid Tumor 2

Interventions

fludarabine phosphate 29Etoposide 26pegaspargase 24Peripheral Blood Stem Cell Transplantation 23Cyclophosphamide 23Whole-Body Irradiation 21Mycophenolic Acid 21Gemcitabine 19Busulfan 19Methotrexate 16Dexamethasone 16Tacrolimus 15Cyclosporine 14Antilymphocyte Serum 13Radiotherapy 12Oxaliplatin 10Rituximab 9Melphalan 8Asparaginase 8Doxorubicin 7Bortezomib 7spartalizumab 6Vorinostat 6Lenalidomide 6Flow Cytometry 6tislelizumab 5Vincristine 5Therapeutics 5Methylprednisolone 5Everolimus 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Lymphoma, Extranodal NK-T-Cell × selinexor × Clear all
NCT07554482 2026-04-28

Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma

Beijing Tongren Hospital

Phase 2 Not yet recruiting
34 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

NCT07276698 2025-12-11

Clinical Study on Maintenance Therapy With Selinexor Combined With Azacitidine After Allogeneic Hematopoietic Stem Cell Transplantation for NK/T-cell Lymphoma

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Phase 2 Not yet recruiting
39 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

NCT06573138 2024-08-27

Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL

Ruijin Hospital

Phase 2 Not yet recruiting
18 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡